Total Payments
$1,161
2024 Payments
$18.90
Companies
13
Transactions
22
Medicare Patients
1,878
Medicare Billing
$626,868
Payment Breakdown by Category
Food & Beverage$635.84 (54.8%)
Consulting$525.00 (45.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $635.84 | 21 | 54.8% |
| Consulting Fee | $525.00 | 1 | 45.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ceribell, Inc. | $525.00 | 1 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $210.80 | 7 | $0 (2024) |
| BOSTON SCIENTIFIC CORPORATION | $117.78 | 1 | $0 (2021) |
| ABBVIE INC. | $67.95 | 3 | $0 (2022) |
| Adamas Pharmaceuticals, Inc. | $46.41 | 2 | $0 (2019) |
| PORTOLA PHARMACEUTICALS, INC. | $34.44 | 1 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $27.97 | 1 | $0 (2023) |
| Chiesi USA, Inc. | $24.55 | 1 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $24.28 | 1 | $0 (2021) |
| Biogen, Inc. | $23.96 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18.90 | 1 | AstraZeneca Pharmaceuticals LP ($18.90) |
| 2023 | $731.06 | 6 | Ceribell, Inc. ($525.00) |
| 2022 | $80.60 | 4 | ABBVIE INC. ($67.95) |
| 2021 | $184.62 | 5 | BOSTON SCIENTIFIC CORPORATION ($117.78) |
| 2020 | $21.86 | 1 | GENZYME CORPORATION ($21.86) |
| 2019 | $123.80 | 5 | Adamas Pharmaceuticals, Inc. ($46.41) |
All Payment Transactions
22 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/22/2024 | AstraZeneca Pharmaceuticals LP | ANDEXXA (Biological) | Food and Beverage | In-kind items and services | $18.90 | General |
| Category: Rare Disease | ||||||
| 11/15/2023 | AstraZeneca Pharmaceuticals LP | ANDEXXA (Biological) | Food and Beverage | In-kind items and services | $118.80 | General |
| Category: Rare Disease | ||||||
| 05/24/2023 | AstraZeneca Pharmaceuticals LP | ANDEXXA (Biological) | Food and Beverage | In-kind items and services | $17.89 | General |
| Category: Rare Disease | ||||||
| 05/11/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $27.97 | General |
| Category: Cardiovascular | ||||||
| 04/25/2023 | Ceribell, Inc. | Ceribell Rapid Response EEG (Device) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Neurology | ||||||
| 03/16/2023 | Microtransponder, Inc. | — | Food and Beverage | Cash or cash equivalent | $16.85 | General |
| 03/08/2023 | Chiesi USA, Inc. | CLEVIPREX (Drug) | Food and Beverage | Cash or cash equivalent | $24.55 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/17/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $20.42 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/13/2022 | AstraZeneca Pharmaceuticals LP | ANDEXXA (Biological) | Food and Beverage | In-kind items and services | $12.65 | General |
| Category: Rare Disease | ||||||
| 05/12/2022 | ABBVIE INC. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $24.89 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/09/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $22.64 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/20/2021 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $15.59 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/29/2021 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $14.47 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/02/2021 | BOSTON SCIENTIFIC CORPORATION | WATCHMAN (Device) | Food and Beverage | In-kind items and services | $117.78 | General |
| Category: STRUCTURAL HEART | ||||||
| 08/23/2021 | Merck Sharp & Dohme Corporation | DIFICID (Drug) | Food and Beverage | In-kind items and services | $24.28 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/30/2021 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $12.50 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/24/2020 | GENZYME CORPORATION | AUBAGIO (Drug) | Food and Beverage | In-kind items and services | $21.86 | General |
| Category: Neurology | ||||||
| 11/13/2019 | Biogen, Inc. | TYSABRI (Biological), TECFIDERA | Food and Beverage | In-kind items and services | $23.96 | General |
| Category: NEUROLOGY | ||||||
| 10/22/2019 | Adamas Pharmaceuticals, Inc. | GOCOVRI (Drug) | Food and Beverage | In-kind items and services | $23.44 | General |
| Category: PD | ||||||
| 09/04/2019 | Adamas Pharmaceuticals, Inc. | GOCOVRI (Drug) | Food and Beverage | In-kind items and services | $22.97 | General |
| Category: PD | ||||||
| 09/03/2019 | Lundbeck LLC | NORTHERA (Drug) | Food and Beverage | Cash or cash equivalent | $18.99 | General |
| Category: NEUROLOGY | ||||||
| 07/17/2019 | PORTOLA PHARMACEUTICALS, INC. | ANDEXXA (Biological) | Food and Beverage | Cash or cash equivalent | $34.44 | General |
| Category: HEMATOLOGY/NEUROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 471 | 1,137 | $710,448 | $175,632 |
| 2022 | 7 | 531 | 1,148 | $594,720 | $160,261 |
| 2021 | 7 | 529 | 1,021 | $386,760 | $165,164 |
| 2020 | 5 | 347 | 733 | $299,991 | $125,811 |
Total Patients
1,878
Total Services
4,039
Medicare Billing
$626,868
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 280 | 846 | $628,578 | $146,797 | 23.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 146 | 243 | $64,638 | $23,998 | 37.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 18 | 18 | $9,252 | $2,549 | 27.5% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2023 | 16 | 18 | $5,760 | $1,597 | 27.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 12 | $2,220 | $691.72 | 31.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 222 | 591 | $439,113 | $109,877 | 25.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 171 | 398 | $105,868 | $34,844 | 32.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 46 | 46 | $23,644 | $7,676 | 32.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 39 | 55 | $10,175 | $3,270 | 32.1% |
| 99284 | Emergency department visit for problem of high severity | Facility | 2022 | 19 | 20 | $6,240 | $2,079 | 33.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 22 | 24 | $8,280 | $2,053 | 24.8% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 12 | 14 | $1,400 | $463.06 | 33.1% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 301 | 711 | $326,349 | $134,118 | 41.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 134 | 205 | $34,645 | $18,399 | 53.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 38 | 39 | $13,143 | $6,786 | 51.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 20 | 21 | $4,095 | $1,857 | 45.3% |
| 99292 | Critical care delivery critically ill or injured patient | Facility | 2021 | 14 | 18 | $3,762 | $1,716 | 45.6% |
| 99284 | Emergency department visit, problem of high severity | Facility | 2021 | 11 | 11 | $2,750 | $1,289 | 46.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 11 | 16 | $2,016 | $999.04 | 49.6% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 236 | 596 | $273,564 | $112,070 | 41.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 62 | 85 | $14,365 | $7,688 | 53.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 20 | 21 | $7,077 | $3,679 | 52.0% |
| 99292 | Critical care delivery critically ill or injured patient | Facility | 2020 | 13 | 13 | $2,717 | $1,245 | 45.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 16 | 18 | $2,268 | $1,130 | 49.8% |
About Dr. Basit Rahim, MD
Dr. Basit Rahim, MD is a Vascular Neurology healthcare provider based in Mission Viejo, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/30/2013. The National Provider Identifier (NPI) number assigned to this provider is 1003253071.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Basit Rahim, MD has received a total of $1,161 in payments from pharmaceutical and medical device companies, with $18.90 received in 2024. These payments were reported across 22 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($635.84).
As a Medicare-enrolled provider, Rahim has provided services to 1,878 Medicare beneficiaries, totaling 4,039 services with total Medicare billing of $626,868. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Vascular Neurology
- Location Mission Viejo, CA
- Active Since 05/30/2013
- Last Updated 10/28/2020
- Taxonomy Code 2084V0102X
- Entity Type Individual
- NPI Number 1003253071
Products in Payments
- Ceribell Rapid Response EEG (Device) $525.00
- ANDEXXA (Biological) $202.68
- WATCHMAN (Device) $117.78
- GOCOVRI (Drug) $46.41
- DALVANCE (Drug) $43.06
- BRILINTA (Drug) $42.56
- ELIQUIS (Drug) $27.97
- TEFLARO (Drug) $24.89
- CLEVIPREX (Drug) $24.55
- DIFICID (Drug) $24.28
- TYSABRI (Biological) $23.96
- AUBAGIO (Drug) $21.86
- NORTHERA (Drug) $18.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.